Celestial Biolabs
No trades in 1Y
Peer Comparison
Healthcare › Pharmaceuticals & Biotechnology › Biotechnology
| ₹888.30 | 86.66 | ₹47,903 Cr | 16.45 | 0.23% | 22.30% | 30.40% | ₹2,002 Cr | ₹576 Cr | |
| ₹278.40 | 18.79 | ₹3,125 Cr | 1.87 | 1.95% | 10.20% | 14.00% | ₹750 Cr | ₹172 Cr | |
| ₹35.93 | — | ₹163 Cr | 4.06 | 0.00% | −2.92% | −2.92% | ₹0 Cr | −₹1 Cr | |
| ₹0.44 | — | ₹18 Cr | 0.27 | 0.00% | 0.96% | 1.31% | ₹5 Cr | ₹0 Cr | |
| ₹55.67 | 1,855.67 | ₹16 Cr | 4.34 | 0.00% | 0.77% | 1.02% | ₹0 Cr | ₹0 Cr | |
| Celestial Biolabs (this company) | — | — | — | — | — | −18.90% | −3.84% | ₹0 Cr | — |
| Median 6 companies | ₹55.67 | 86.66 | ₹163 Cr | 4.06 | 0.00% | 0.87% | 1.17% | ₹3 Cr | ₹0 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company. 2 companies are not shown because they are not listed on an exchange we cover.
Key Insights
No strengths listed
Weaknesses
4- Company has low interest coverage ratio.
- Contingent liabilities of Rs.1.29 Cr.
- Company might be capitalizing the interest cost
- Company has high debtors of 7,966 days.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bearish | 11 | 3 | 5 |
| Oscillators | Strong Bullish | 1 | 3 | 5 |
| Moving Averages | Strong Bearish | 10 | 0 | 0 |
Oscillators
Strong Bullish
Overall
Strong Bearish
Moving Averages
Strong Bearish
Key readings
- RSI (14)
- 25.48
- Bullish
- MACD (12,26,9)
- −0.20
- Bullish
- SMA (50)
- 2.51
- Bearish
- SMA (200)
- 3.43
- Bearish
As of , the latest day with price data, so these readings are not current.
Growth Rate
Annual windows: The latest annual results are more than two years old, so no annual growth is shown.
Trailing twelve months: The latest quarterly results are more than a year old.
Quarterly Results
₹ CrResults for the period ended Mar 2024 were due by 30 May 2024 and are not in this table yet.
| Particulars | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0.06 | 0.06 | 0.04 | 0.03 | 0.04 | 0.02 | 0.04 | 0.04 |
| Expenses | 0.33 | 0.15 | 0.11 | 0.18 | 0.27 | 0.11 | 0.07 | 0.07 |
| Operating Profit | −0.27 | −0.09 | −0.07 | −0.15 | −0.23 | −0.09 | −0.03 | −0.03 |
| OPM % | −450% | −150% | −175% | −500% | −575% | −450% | −75% | −75% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0.01 | 0 | 0 | 0 |
| Depreciation | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| PBT | −0.28 | −0.1 | −0.08 | −0.16 | −0.25 | −0.1 | −0.03 | −0.04 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | −0.28 | −0.1 | −0.08 | −0.15 | −0.25 | −0.1 | −0.03 | −0.04 |
| EPS (₹) | −0.12 | −0.04 | −0.04 | −0.07 | −0.11 | −0.04 | −0.01 | −0.02 |
Profit & Loss
₹ Cr| Particulars | Mar 2022 | Mar 2023 | TTM |
|---|---|---|---|
| Sales | 0.15 | 0.17 | 0.14 |
| Expenses | 0.49 | 0.71 | 0.52 |
| Operating Profit | −0.34 | −0.54 | −0.38 |
| OPM % | −226.67% | −317.65% | −271.43% |
| Other Income | 0 | 0 | 0 |
| Interest | 0.04 | 0.01 | 0.01 |
| Depreciation | 0.03 | 0.03 | 0.04 |
| PBT | −0.41 | −0.58 | −0.43 |
| Tax % | 0% | 0% | — |
| Net Profit | −0.41 | −0.58 | −0.41 |
| EPS (₹) | −0.18 | −0.26 | −0.18 |
| Div. Payout % | 0% | 0% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2022 | Mar 2023 | Sep 2023 |
|---|---|---|---|
| Equity Capital | 22.59 | 22.59 | 22.59 |
| Reserves | −19.24 | −19.81 | −19.94 |
| Borrowings | 11.54 | 12.03 | 12.04 |
| Other Liabilities | 2.29 | 2.43 | 2.49 |
| Total Liabilities | 17.18 | 17.24 | 17.18 |
| Fixed Assets | 0.1 | 0.08 | 0.06 |
| CWIP | 12.82 | 12.82 | 12.82 |
| Investments | 0 | 0 | 0 |
| Other Assets | 4.26 | 4.34 | 4.3 |
| Total Assets | 17.18 | 17.24 | 17.18 |
Cash Flow
₹ Cr| Particulars | Mar 2022 | Mar 2023 |
|---|---|---|
| Operating | −0.28 | −0.36 |
| Investing | 0 | 0 |
| Financing | 0.26 | 0.38 |
| Net Cash Flow | −0.02 | 0.02 |
| Free Cash Flow | −0.28 | −0.37 |
| CFO/EBITDA | 82 | 67 |
Ratios
| Particulars | Mar 2022 | Mar 2023 |
|---|---|---|
| Debtor Days | 9,320 | 7,966 |
| Inventory Days | 86.9 | 99.55 |
| Days Payable | 452 | 1,161 |
| Cash Conversion Cycle | 8,955 | 6,904 |
| Working Capital Days | −2,628 | −2,512 |
| ROCE % | — | −3.84% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Celestial Biolabs insights
54 extracted metrics across FY09–FY24.
Documents
Frequently Asked Questions about Celestial Biolabs
What does Celestial Biolabs Ltd do?
Where is Celestial Biolabs Ltd (CELESTIAL) listed?
Which sector does Celestial Biolabs Ltd belong to?
Company Information
Celestial Biolabs is engaged in activities of manufacturingof Ayurvedic products and Trading of Feed suppliments.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/CELESTIAL.md for Celestial Biolabs Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.